Immunotherapy has emerged as a breakthrough treatment for cancer.
Several stakes are involved in the development of this revolutionary therapy – clinical, scientific, ethical and regulatory.
The French Society for Cancer Immunotherapy (FITC) was created to unite all the actors involved in the success of immunotherapy within a single body. The FITC represents French expertise at both national and international arenas in this new era of cancer therapy.
Our mission
Facilitate pluri-disciplinary interactions and communication
By developing digital platforms, organizing scientific meetings and training, we bring together scientists, clinicians, patients, ethics committees and regulatory bodies.
Promote medical and scientific research in cancer immunology and immunotherapy
By encouraging collaborative research between scientific and clinical laboratories while facilitating the development of novel diagnostic tests, treatments and therapeutic molecules.
Advance education of patients and their families
A key for the successful implementation of immunotherapy, the FITC is dedicated to developing accessible-for-all tools that will help patients through their treatment notably in understanding and managing side-effects.
Improve access to immunotherapy
Presently in France, access to immunotherapy is a major challenge. The FITC represents clinicians, healthcare workers and scientists working with governing bodies to improve patient access to immunotherapy.
A key strategy being spearheaded by the FITC is to increase visibility of clinical trials open for inclusion and define national recommendations for cancer immunotherapy.
The bureau
Aurélien MARABELLE
Président
Diane DAMOTTE
Vice-Présidente
Jean-Yves BLAY
Trésorier
Roch HOUOT
Secrétaire Général
Marion ALCANTARA
Secrétaire Générale Adjointe
The board of directors
Marion ALCANTARA
Jean-Yves BLAY
Nathalie CHAPUT-GRAS
Stéphane DALLE
Diane DAMOTTE
Stéphane DEPIL
Brigitte DRENO
Jérôme GALON
Carlos GOMEZ
Roch HOUOT
Antoine ITALIANO
Céleste LEBBE
Aurélien MARABELLE
Eric TARTOUR
Laurence ZITVOGEL
With the support of
